Department of Medical Oncology, Vall d'Hebron University Hospital, Passeig de la Vall d'Hebron, 119, Barcelona, Catalunya 08035, Spain.
Department of Medical Oncology, Vall d'Hebron University Hospital, Passeig de la Vall d'Hebron, 119, Barcelona, Catalunya 08035, Spain; Medicine, Università degli Studi della Campania Luigi Vanvitelli, Caserta, Campania, Italy.
Hematol Oncol Clin North Am. 2022 Jun;36(3):507-520. doi: 10.1016/j.hoc.2022.02.006. Epub 2022 May 13.
Currently, clinicopathologic characteristics of colon cancer tumors guide the selection of patients suitable for adjuvant therapy. Circulating tumor DNA (ctDNA) analysis after surgery has a strong correlation with prognosis, and positive ctDNA status defines a subset of patients with high risk of recurrence. Ongoing interventional adjuvant trials in colon cancer including ctDNA analyses will determine the predictive value of ctDNA in the adjuvant setting. For patients with stage III colon cancer, noninferiority of 3 months of adjuvant therapy compared with 6 months has not been demonstrated. However, for selected subgroups, the shorter duration of therapy may limit toxic effects without impairing clinical outcomes.
目前，结肠癌肿瘤的临床病理特征指导着适合辅助治疗的患者选择。手术后循环肿瘤 DNA（ctDNA）分析与预后具有很强的相关性，阳性 ctDNA 状态定义了一部分复发风险高的患者。正在进行的包括 ctDNA 分析的结肠癌干预性辅助试验将确定 ctDNA 在辅助治疗中的预测价值。对于 III 期结肠癌患者，与 6 个月相比，3 个月的辅助治疗非劣效性尚未得到证实。然而，对于某些亚组患者，较短的治疗持续时间可能不会影响临床结局，但不会限制毒性作用。
